NCT01519921View on ClinicalTrials.gov

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.

PHASE4CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Hepatitis B, Chronic

Interventions

DRUG

peginterferon alfa-2a [Pegasys]

Peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once a week for 48 weeks

Trial Locations (7)

14647

Seoul

41944

Daegu

49241

Busan

03722

Seoul

05505

Seoul

06351

Seoul

08308

Seoul

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01519921 - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B. | Biotech Hunter | Biotech Hunter